 Mutations in genes employed in DNA mismatch repair (MMR) cause a high mutation rate.In tumors, such frequent subsequent mutations often generate "non-self" immunogenic antigens.A human Phase II clinical trial, with 41 patients, evaluated one synthetic lethal approach for tumors with or without MMR defects.